A Phase 2 interventional study of Roflumilast Cream 0.3% and Roflumilast Cream 0.15% in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 2nd registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast cream 0.3% topically applied QD for 12 weeks.
Drug: Roflumilast Cream 0.3%
Roflumilast cream 0.15% topically applied QD for 12 weeks.
Drug: Roflumilast Cream 0.15%
Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.
Drug: Vehicle Cream
Applied once daily for 12 weeks
Also known as: ARQ-151
Applied once daily for 12 weeks
Also known as: ARQ-151
Applied once daily for 12 weeks
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
Time frame: Week 6
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
Time frame: Weeks 4, 8, and 12
Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score
The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head \[h\]: 10% of a person's skin; arms \[a\] 20%; trunk \[t\] 30%; legs (l\] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percent Change From Baseline in Body Surface Area (BSA) Affected
The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline
The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.
Time frame: Weeks 4, 6, 8, and 12
Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score
The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction
The percentage of participants who had baseline WI-NRS scores ≥6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline
The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline
The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score
The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Change From Baseline in Dermatology Life Quality Index (DLQI) Score
The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") \[2 questions are scored 0 to 3 and 8 questions are scored 0 to 4\]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.
Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12
Responses to Individual Questions of the Psoriasis Symptom Diary (PSD)
Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.
Time frame: Weeks 4, 6, 8, and 12
Adult (≥18 years of age) male or female participants with chronic plaque psoriasis were recruited at 30 study sites in the US and Canada.
| Milestone | Rolumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Started | 109 | 113 | 109 |
| Completed | 102 | 104 | 86 |
| Not completed | 7 | 9 | 23 |
| Withdrew: Adverse event | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 4 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 5 | 12 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6 | 28.0 | 22.8 | 8.3 |
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 14.5 | 9.0 | 4.4 |
| Week 8 | 37.9 | 30.6 | 11.9 |
| Week 12 | 37.5 | 32.1 | 16.3 |
The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head \[h\]: 10% of a person's skin; arms \[a\] 20%; trunk \[t\] 30%; legs (l\] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.
| score on a scale | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -40.08 ± 46.811 | -47.32 ± 29.717 | -18.01 ± 46.622 |
| Week 6 | -53.15 ± 46.470 | -59.73 ± 32.409 | -16.42 ± 58.385 |
| Week 8 | -59.09 ± 49.290 | -65.12 ± 31.97 | -18.47 ± 63.777 |
| Week 12 | -59.48 ± 54.881 | -68.03 ± 33.021 | -13.65 ± 70.731 |
The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.
| percentage of change | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -21.74 ± 34.381 | -23.25 ± 27.084 | -5.33 ± 31.834 |
| Week 6 | -34.88 ± 39.530 | -33.41 ± 32.136 | -8.19 ± 40.989 |
| Week 8 | -41.58 ± 42.816 | -40.49 ± 34.379 | -7.40 ± 52.859 |
| Week 12 | -48.56 ± 46.077 | -47.50 ± 36.304 | -6.74 ± 51.469 |
The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 10.0 | 6.9 | 4.4 |
| Week 6 | 23.9 | 17.4 | 8.0 |
| Week 8 | 32.2 | 24.5 | 9.8 |
| Week 12 | 31.3 | 27.4 | 13.6 |
The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 46.6 | 43.8 | 17.6 |
| Week 6 | 73.4 | 43.7 | 29.4 |
| Week 8 | 87.1 | 60.9 | 36.1 |
| Week 12 | 94.3 | 32.4 | 24.3 |
The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.
| score on a scale | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -2.8 ± 2.53 | -1.9 ± 2.45 | -1.1 ± 2.20 |
| Week 6 | -3.3 ± 2.56 | -2.6 ± 2.73 | -1.3 ± 2.67 |
| Week 8 | -3.5 ± 2.59 | -2.9 ± 2.73 | -1.5 ± 3.00 |
| Week 12 | -3.4 ± 2.76 | -3.2 ± 2.84 | -1.3 ± 2.76 |
The percentage of participants who had baseline WI-NRS scores ≥6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 50.9 | 35.4 | 24.9 |
| Week 6 | 52.8 | 57.0 | 34.5 |
| Week 8 | 64.6 | 58.2 | 42.3 |
| Week 12 | 62.8 | 70.1 | 32.9 |
The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 13.3 | 7.6 | 10.5 |
| Week 6 | 24.1 | 22.2 | 9.6 |
| Week 8 | 31.3 | 23.0 | 13.2 |
| Week 12 | 34.1 | 31.1 | 16.0 |
The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | 6.0 | 1.3 | 2.3 |
| Week 6 | 14.3 | 2.3 | 3.2 |
| Week 8 | 16.9 | 7.4 | 6.0 |
| Week 12 | 20.6 | 13.7 | 7.8 |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.
| percentage of participants | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -32.7 ± 34.61 | -32.7 ± 35.08 | -22.9 ± 31.85 |
| Week 6 | -37.8 ± 35.71 | -38.0 ± 37.88 | -24.6 ± 38.15 |
| Week 8 | -40.5 ± 36.62 | -40.1 ± 39.04 | -26.9 ± 41.78 |
| Week 12 | -40.8 ± 41.12 | -43.4 ± 40.44 | -23.0 ± 41.38 |
The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.
| score on a scale | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -1.1 ± 2.95 | -1.2 ± 2.54 | -1.0 ± 2.74 |
| Week 6 | -1.5 ± 2.94 | -1.3 ± 2.65 | -0.9 ± 2.96 |
| Week 8 | -1.6 ± 2.96 | -1.7 ± 2.75 | -0.9 ± 3.08 |
| Week 12 | -1.8 ± 3.01 | -1.7 ± 2.66 | -1.1 ± 3.33 |
The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") \[2 questions are scored 0 to 3 and 8 questions are scored 0 to 4\]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.
| score on a scale | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4 | -2.2 ± 3.46 | -2.3 ± 4.01 | -1.9 ± 4.29 |
| Week 6 | -2.6 ± 3.64 | -3.1 ± 4.23 | -1.8 ± 4.23 |
| Week 8 | -2.6 ± 3.68 | -3.5 ± 4.57 | -1.6 ± 4.77 |
| Week 12 | -2.6 ± 4.48 | -4.2 ± 4.92 | -1.4 ± 5.28 |
Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.
| score on a scale | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 4: Itching | 3.0 ± 2.87 | 3.3 ± 2.88 | 4.2 ± 3.02 |
| Week 4: Pain | 1.8 ± 2.67 | 1.6 ± 2.46 | 2.6 ± 2.89 |
| Week 6: Itching | 2.7 ± 2.70 | 2.8 ± 2.80 | 4.2 ± 2.96 |
| Week 6: Pain | 1.5 ± 2.39 | 1.5 ± 2.52 | 2.3 ± 2.70 |
| Week 8: Itching | 2.4 ± 2.70 | 2.4 ± 2.69 | 4.0 ± 2.92 |
| Week 8: Pain | 1.3 ± 2.48 | 1.3 ± 2.36 | 2.4 ± 2.76 |
| Week 12: Itching | 2.3 ± 2.78 | 2.2 ± 2.65 | 4.3 ± 3.14 |
| Week 12: Pain | 1.2 ± 2.37 | 1.2 ± 2.35 | 2.5 ± 2.94 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Cream 0.3% | 0/109 (0%) | 1/109 (0.9%) | 8/109 (7.3%) |
| Roflumilast Cream 0.15% | 0/113 (0%) | 1/110 (0.9%) | 7/110 (6.4%) |
| Vehicle Cream | 0/109 (0%) | 2/107 (1.9%) | 0/107 (0%) |
| Event | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Basal ganglia infarctNervous system disorders | 0/109 | 0/110 | 1/107 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/109 | 0/110 | 1/107 |
| Chest painCardiac disorders | 1/109 | 0/110 | 0/107 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/109 | 1/110 | 0/107 |
| Event | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/109 | 7/110 | 0/107 |
| Age, Continuous(years) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 51.7 ± 14.11 | 54.4 ± 14.20 | 55.5 ± 13.49 | 53.9 ± 13.99 |
| Sex: Female, Male(Participants) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Female | 53 | 51 | 42 | 146 |
| Male | 56 | 62 | 67 | 185 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 26 | 25 | 76 |
| Not Hispanic or Latino | 84 | 87 | 84 | 255 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 8 | 7 | 5 | 20 |
| Native Hawaiian or Other Pacific Islander | 12 | 10 | 7 | 29 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 82 | 95 | 92 | 269 |
| More than one race | 7 | 1 | 4 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Whole Body Investigator Global Assessment (IGA) Score(Participants) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 | 0 |
| 1 - Almost Clear | 0 | 0 | 0 | 0 |
| 2 - Mild | 17 | 18 | 11 | 46 |
| 3 - Moderate | 84 | 83 | 89 | 256 |
| 4 - Severe | 8 | 12 | 9 | 29 |
| Intertriginous Area Investigator Global Assessment (I-IGA) Score(Participants) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| 1 - Almost Clear | 1 | 2 | 0 | 3 |
| 2 - Mild | 6 | 12 | 7 | 25 |
| 3 - Moderate | 8 | 3 | 8 | 19 |
| 4 - Severe | 1 | 1 | 2 | 4 |
| Itch-Related Sleep Loss Score(score on a scale) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 2.9 ± 3.24 | 3.0 ± 3.19 | 3.4 ± 3.18 | 3.1 ± 3.20 |
| Percentage of Body Surface Area (BSA) Affected(percentage of body surface area) | Roflumilast Cream 0.3% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 6.33 ± 4.005 | 6.44 ± 3.915 | 6.43 ± 3.597 | 6.40 ± 3.833 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in May 2019, 8 months.
Results were first posted in Aug 2022, 3 years 2 months after primary completion. A results delay was requested in Aug 2020.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →